



## Microalgal Nanocarrier Drug Delivery in Cancer Therapy

<sup>1</sup>Srishti Roy, <sup>2</sup>Tamalika Chakraborty\*, <sup>3</sup>Chanda Malakar\*

<sup>1</sup>Department of Microbiology, Master of Science, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, West Bengal, India.

<sup>2</sup>Department of Life Science, Assistant Professor, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, West Bengal, India.

<sup>3</sup>Department of Microbiology, Master of Science, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, West Bengal, India.

\*Corresponding author's E-mail: [tamalika.chakraborty@gnipst.ac.in](mailto:tamalika.chakraborty@gnipst.ac.in)

Received: 10-04-2023; Revised: 20-06-2023; Accepted: 26-06-2023; Published on: 15-07-2023.

### ABSTRACT

A suitable treatment plan is needed for cancer, a common medical condition. Chemotherapy also radiation are the two majorly common therapeutic modalities for the treatment of cancer; yet, serious side effects have been linked to these therapies. Radiation, for instance, can negatively impact a patient's immune system function. By offering cutting-edge corrective remedies, these adverse effects may be reduced. Microalgae also contain various types of bioactive molecules, including carotenoids, different kinds of polysaccharides, vitamins, sterols, fibers, minerals, etc. Considerable advancement in the creation of anti-malignant medications may be made possible by the vast amount of unused biomass found in microalgae and their excellent diversity of chemical components. Previously, this property of microalgal biodiversity was used for profit to produce dietary supplements and gelling agents. However, recently, several studies aimed at examining the possible anti-carcinogenic activity of microalgal extracts came to the majority of conclusions that they could induce programmed cancer cell death on either caspase-dependent or independent routes. Diatoms are unicellular photosynthetic creatures that are highly productive and have short growth cycles. They are important for the biogeochemical cycling of nitrogen, carbon, and silica. The bio-silica of diatoms has the potential to be a successful medication administration for targeted cancer remedial treatment because of its, biodegradability, bio-compatibility, nano-porosity, and substantial surface area. In this review work, we have talked about the many microphytal species that have thwart tumor activity and the tumor cell lines that have been modified using microalgal extracts that have been found to have an inhibitory effect on cell cycle and proliferation.

**Keywords:** Chemotherapy, diatoms, treatment, microalgae, tumor, microphyte.

QUICK RESPONSE CODE →

DOI:

10.47583/ijpsrr.2023.v81i01.029



DOI link: <http://dx.doi.org/10.47583/ijpsrr.2023.v81i01.029>

### INTRODUCTION

The second leading cause of death worldwide is cancer. Additionally, it was responsible for 8.8 million fatalities in 2015. Thus, cancer was the cause of almost 1 in 6 fatalities. Uncontrolled cellular proliferation in malignant tumors is associated with significant pathologic alterations<sup>1</sup>. Uncontrollable tumors are presently more than 200 dissimilar forms are displayed, as well as numerous malignancies that can spread to other organs and cause lethal metastatic tumors. The elimination of cancer has received a lot of attention due to its high level of impact<sup>2</sup>. Chemotherapy, which uses medications that can either kill cancerous cells or at least slow their growth, is frequently used as the initial line of treatment for cancer<sup>3</sup>. These medications are linked by toxicity, which can range from a minor reaction to a serious sickness that poses a life-threatening threat<sup>4</sup>. Hair loss and appetite loss were among the many chemotherapy medications adverse effects. As a result,

various sources should be examined for potential anticancer drugs<sup>5</sup>.

In general, algae are the primary producer of several natural anticancer amalgams or their metabolites. The biological effects of phytochemicals obtained from plants have been the focus of many studies, whereas microalgae-derived phytochemicals have received very less attention<sup>6</sup>. Phytochemicals with more potential biological activity are generated from microalgae than those with a terrestrial origin (plant phytochemicals). Compared to many other plant species, microalgae exhibit a variety of phenolic classes that are highly unique (medicinal plants, fruits, and vegetables)<sup>7</sup>. In comparison to some plants, microalgae have a higher concentration of chlorophyll and carotenoids. The eukaryotic microbes are thought to be a nice source of proteins and various nutrients<sup>8</sup>. Additionally, these bacteria create a wide variety of bioactive substances that may be sources of immunomodulatory molecules, anti-microbial, anti-inflammatory, and anti-cancer in addition to having other health-promoting benefits<sup>9</sup>. The phytonutrient parts of microalgae, particularly the peripheral metabolites, which are extraordinary sources of bioactive chemicals, are generally the foundation for the pharmacological activities of these organisms<sup>10</sup>.


Peptides have a significant potential for application in pharmaceuticals, although they have not been extensively



studied as a class of chemicals<sup>11</sup>. Peptides are small, under 3 kDa molecular weight amino acid chains that typically have 2 to 20 units. Bioactive peptides play key roles in development regulation, cell signaling, and defense response in plants.

Plant-derived proteins can also be made in a lab by the catalytic breakdown of withdrawn proteins or by maceration ('in the gastrointestinal system') of proteins from eaten algal biomass<sup>12 13</sup>. The application of carbon compounds, one of the many beneficial by-products produced by microalgae, is in medicine, cosmetics, and

pharmaceuticals. The presence of lipids, proteins, polysaccharides, vitamins, and antioxidants are only a few of the other components found in microalgae.<sup>14 15</sup> Microalgae improve the host's defense by boosting the activity of natural killer cells, stimulating the immune system, and reducing the proliferation of cancer cells. The prevention of carcinogenesis was therefore thought to be in part due to microalgae. We have made an effort to cover the profitable aspect of microalgae bio-products in our review because they can essentially be used as anticancer medicines<sup>16 17</sup>.



**Figure 1:** The majorly used microalgal-derived compounds; microalgal biomass is a viable origin for biofuel & biologically active goods.

### Microalgae and its Versatile Health Benefits

A diverse category of photosynthetic microbes known as microalgae, whose biochemical compositions range greatly due to their evolutionary and phylogenetic variety<sup>18 19</sup>. In reaction to changes in their environment, these bacteria can biosynthesize, collect, and generate a broad variety of primary and secondary metabolites, many of which are extremely important compounds with industrial uses and positive health effects<sup>20</sup>.


Although different populations have used microalgae as a food source for thousands of years, mercantile abuse of this resource only began in the last few decades, when there was concern over a potential shortage of protein due to the world's rapid population growth<sup>21 22</sup>. For hundreds of years, people have used microalgae as food or nutritional supplements<sup>23</sup>. Around AD 1300, the 'Aztecs' employed the cyanobacterium spirulina ('*Arthrospira maxima*', '*Arthrospira platensis*') from 'Lake Texcoco (Mexico)'. The

blue-green masses that the local fisherman collected from the lakes and turned into the dry cake known as "tecuilatli" were reported by 'Spanish chroniclers'<sup>24</sup>. The people of 'Chad' have been regularly obtaining and utilizing spirulina, also known as "dihé," from 'Lake Kossorom'. Nostoc, a type of filamentous cyanobacteria, has also long been consumed as food<sup>25</sup>. The '*N. Punctiforme*', '*N. flagelliforme*' and '*N. commune*' also called as "fa cai" and "lake plum," are traditionally eaten in 'China', 'South America', etc<sup>26 27</sup>.

Algae are divided into four taxonomic groupings in the Protista kingdom based on their color (red, brown, blue, and green)<sup>28 29</sup>. Microalgae are essentially composed of various ratios of lipids, carbohydrates, proteins, and nucleic acids; these ratios can vary depending on the species and growing circumstances. Additionally, they include carbohydrates, vitamins, minerals, and colours<sup>30 31</sup>. For instance, an examination of the cells of marine microalgae (*Nannochloropsis*) revealed the pigment, amino acids, and omega-3 fatty acid contents of the microalgae.<sup>32 33 34</sup>

**Table 1:** Two main sources of Microalgae<sup>34</sup>

Freshwater Algae	Marine Algae
The ten primary phyla of freshwater algae can be distinguished microscopically. In addition, other minor phyla have little impact on the freshwater environment, including 'Eustigmatophyta' (three species), 'Prasinophyta' (13 species), 'Glaucophyta' (two species each), 'Haptophyta' (five species), and 'Raphidophyta'. A taxonomical range of microalgae can generally be determined from the large species diversity of fresh water and terrestrial algae.	The unique beneficial genes and metabolites come from this key primary source. More than 30,000 distinct microalgae species have been identified to date. Eukaryotic species like diatoms and prokaryotic organisms are included in the heterogeneous marine microalgae.



**Figure 2:** The potential cell mechanism(s) underlying microalgal anti-tumor activity and the potential function of the involved molecules.

**Table 2:** Types of microalgae, their phytoconstituents, and anti-cancer property<sup>4</sup>

Microalgae	Phytoconstituents	Anti-cancer property
<i>Chondrus crispus</i> Brown and Red algae	Beta-carotene	Prevents cell cycle arrest and apoptosis from occurring, as well as the development of numerous human colon cancer cell lines. Decreases the important cell cycle regulator cyclin A
<i>Cystoseira</i> sp.	Terpenoids	Extremely effective anti-platelet aggregation and anti-tumor action
Red algae	Phycocyanin and phycoerythrin	In 'HepG2' and 'A549' cells, cell proliferation is inhibited by inhibiting the tumor cell cycle, triggering tumor cell death, and activating autophagy.
<i>Halimeda</i> sp.	Catechin, flavonoids, phlorotannins, etc	Regulation of oxidative stress-related pathways. Inhibition of cell cycle progression and alteration of enzymes that scavenge reactive oxygen species (ROS).
<i>Turbinaria conoides</i>	Fucoxanthin, alginic acid	Stimulation of cytotoxic natural killer cells and macrophages. The aptitude of polysaccharides to accumulate poisons and heavy metals in the gut and modify them into less hazardous compounds.
<i>Laminaria japonica</i> , <i>Sargassum wightii</i> and most Red algae	Sulfated galactans, Glycosaminoglycan and Fucoxanthin	Selective inhibition of tumor angiogenesis
<i>Porphyra</i> sp.	Porphyran	'RAW264'-induced activation of NF- $\kappa$ B in mouse macrophages results in a reduction of NO generation.
<i>Sargassum</i> sp. and other brown seaweeds and dinoflagellates.	Fucoxanthin	Melanoma cells' motility is weakened

### Anticancer Activity of Microalgae

The antitumor capabilities of various algal resources have recently been revealed to influence several cellular pathways, including cellular cyto-toxication, downregulating tumorcell invasion, and enhancing cancer cell death.<sup>35 36 37 38</sup> Numerous cellular and molecular studies have revealed that chemicals produced from algae have powerful natural anti- malignant properties<sup>39, 40</sup>. Fucoxanthin, found in microalgae, diatoms, and brown seaweeds, is another illustration of this. It has powerful anticancer properties by inhibiting the growth of malignant cells, activating genes that fight cancer, and stopping cell cycles, but it does not affect the apoptosis of tumor cells<sup>41, 42</sup>. A new, successful tumor therapy for humans may become more apparent as data about anticancer resources obtained from algae become more accumulated.<sup>43-45</sup>

### Oncogene and Oncogenic Therapy: An Overview


Cancer is a distinct set of diseases brought on by aberrant cell development as a result of specific flaws. The human body's regular cell life cycle is rigorously controlled by several systems that tell the cells when to divide, grow, differentiate, or die<sup>47-50</sup>. Due to genetic flaws, cancer cells can avoid these controls and continue to grow uncontrollably.

Multiple variables, including genetic abnormalities, environmental conditions, specific viral infections, and occasionally no obvious cause, contribute to the development of cancer. Cancer can start in any area of the body and eventually spread across the entire body (metastasis). A gene with the capacity to cause cancer is known as an oncogene. These genes are frequently expressed at high levels or altered in tumor cells.<sup>51-53</sup> When crucial processes are distorted and dysfunctional, the


majority of normal cells will die quickly and on their own accord (apoptosis). Cells intended for apoptosis may instead survive and proliferate as a result of activated oncogenes.<sup>54, 55</sup> The majority of oncogenes had their roots in proto-oncogenes, which were typically found in genes involved in proliferation, cell growth, or apoptosis suppression. Oncogenes are normal genes that promote cell development that is up-regulated through mutation ('gain-of-function mutation'), which predisposes the cell to cancer.<sup>56, 57</sup> Cancer is typically brought on by a combination of several oncogenes, altered genes that control apoptosis or tumor suppression, and other factors. An advanced kind of cancer treatment known as oncogenic therapy targets particular cancer-causing proteins and biological pathways. To stop cancer cells from growing uncontrollably, it uses drugs that change how they work.<sup>58-60</sup>

### Colorectal cancer

Colorectal cancer risk factors include smoking, drinking alcohol, having inflammatory bowel disease, and having a family history of the illness.<sup>61</sup> The majority of colorectal malignancies, fortunately, start as little precancerous (adenomatous or serrated) polyps. These polyps typically grow slowly until they are huge or cancerous and do not show symptoms.<sup>62 63</sup> As a result, it is possible to identify and remove pre-cancerous polyps before they turn cancerous. Although there are many various types of colorectal polyps, it is believed that adenomas and sessile serrated lesions, which are premalignant cysts, are where most cancers are considered to start. A polyp that is discovered during a colonoscopy is often removed, if it is possible. Following removal during colonoscopies, polyps are analyzed by a pathologist to see if they have malignant or precancerous cells.



**Figure 3:** “The chromosomal instability”, “microsatellite instability” and “CpG IslandMethylator Phenotype” molecular pathways have all been found.



**Figure 4:** Paracrine and endocrine factors originating from adipose tissue regulate the increasing breast cancer cells through molecular processes. The mitogenic response in ‘breast epithelial cells is synergistically induced in obesity by increased ‘insulin’ and ‘IGF-I serum levels that interact with ‘estrogen signaling pathways’. Adipocytes function as the peripheral location of estrogen aromatization and a paracrine source of many adipokines and inflammatory mediators. Leptin is one of the adipokines that can affect a variety of second intracellular messengers involved in the survival and proliferation of breast cancer cells.

**Table 3:** Principal types of genes involved in LC and signaling pathways<sup>68</sup>

Cell Indicating Passage	“Adenocarcinoma Genes involved (%)”	“Squamous Carcinoma Genes involved (%)”	“Small Cell Carcinoma Genes involved (%)”
“TP53”	“50 P53, MDM2”	“80 TP53”	“80-90 TP53”
“RAS/RAF”	“25 KRAS, NF1, BRAF, NRAS”	“22 NF1, KRAS, HRAS, NRAS, RASA1, BRAF”	
“PI3K/AKT”	“10-12 PIK3CA, PTEN, AKT1”	“59 PIK3CA, PTEN, AKT1-3, TSC1-2”	“10 PTEN”
“MYC”	“30 MYC”		‘16-30 MYC, MYCN, MYCL’
“RTK”	‘50 EGFR, ALK, RET, ERBB2, ROS, MET’	“27 EGFR, FGFR1-3, ERBB2/3, DDR2”	“6 FGFR1”
“RB1/CDKNA2”	“15-20 CDKNA2”	“79 CDKNA2, RB1”	“100 RB1, CCNE1”
“Epigenetic regulation”	“22 SMARCA4, ARID1A, SETD2”	“20 MLL2”	“19 EP300, MLL, CREBBP”
“Response to oxidative stress”	“10 KEAP 1”	“KEAP1, CUL3, NRF2”	

**Breast cancer**

The disorder is known as breast cancer characterized used by uncontrolled cell growth in the breast. Lobules, connective tissue, and ducts are the three primary components of a breast. Milk-producing glands are called lobules and are delivered to the nipple by tubes called ducts. The surrounding and unifying tissue is called

connective tissue, where the majority of breast tumors start. While HER2 and ER are the two most often changed pathways in breast cancer, it is now well acknowledged that many other signaling pathways play a role in the disease' etiology. A total of 1,243 mRNAs were examined, and 854 (68.7%) of them were found in breast cancer.<sup>64, 65</sup> Between benign and cancerous tissues, 395 mRNAs showed statistically significant differences (fold change >2).



'33 mRNAs and 105 mRNAs', respectively, are only expressed in normal breast tissues and breast cancer tissues, respectively, of this group of mRNAs. Out of 131 proteins and phosphoproteins, '89' (68%) were found in cancerous tissues, and 57 proteins significantly distinguished tumors from normal tissues. Interestingly, only 3 genes ('CDK6, Vimentin, and SLUG') showed reductions in both protein and mRNA.

### Pleural cancer

Two pliable organs in our chest called the lungs allow us to breathe in O<sub>2</sub> and exhaust CO<sub>2</sub>. When we inhale tobacco smoke, which is full of "cancer-causing chemicals," changes in the lung tissue begin to occur almost immediately (carcinogens). The first damage may be able to be repaired by our body, but with each additional exposure, the healthy cells that line our lungs are gradually eliminated. Cells become dysfunctional as a result of damage over time, which could ultimately result in the growth of cancer. There are two main forms of pleural cancer, "small cell LC", which is more uncommon, and has a faster growth rate and a higher likelihood of developing metastases that were present at the time of diagnosis, and "non- small cell LC", which is more prevalent but has a slower growth rate.[40] More than 7,000 compounds, including over 70 recognized carcinogens, including nitrosamine ketones and 'polycyclic aromatic hydrocarbons' (PAH), which induce genetic changes by forming a complex with DNA, are found in tobacco smoke. The metabolism of the aforementioned carcinogens is activated, and 'glutathione-S-transferases', 'CYP family enzymes' and 'cytochrome P450' all participate in this synthesis (GSTs).<sup>67 68</sup> The aforementioned enzymes' roles have been modified in numerous LC signaling pathways. The majority of them are controlled by oncogenes, which cause the cells to proliferate uncontrollably and avoid apoptosis.

### Contribution of Microalgae in Anti-Cancer Therapy

In the chloroplasts of brown seaweeds, there is a carotenoid called fucoxanthin. A drug sensitivity test was used to assess the antitumor effects of fucoxanthin and its metabolite, "fucoxanthin", on "20" tissue samples taken from surgically removed 'clinical colorectal cancer specimens and six 'colorectal cancer cell lines (CD-DST). At dosages of '20 M', "fucoxanthin" and "fucoxanthin" lowered the "T/C" (%) of the "HCT116", "Caco-2", "DLD-1" cell lines and "WiDr". Fucoxanthinol likewise decreased the "T/C" (%) of 'SW620' cells, but neither carotenoid had any effect on the 'T/C' (%) of 'Colo205' cells. In particular, the 'T/C' (%) of 'Caco-2' and 'WiDr' cells was significantly reduced to 1.40.2 and 12.00.3%, respectively, after being treated with 20 M fucoxanthinol for 24 h. Additionally, in tissue samples from those who had colorectal cancer, 'fucoxanthin and fucoxanthinol' reduced the 'T/C' (%). Hence it would be suggested that the chemotherapeutic drugs fucoxanthin and fucoxanthinol can be useful resources for the treatment of colorectal cancer.<sup>69</sup>

For targeted drug delivery and fluorescence imaging-

guided treatment of breast cancer lung metastases, '*Spirulina platensis*' may be used as a general carrier. To create the DOX-loaded SP '(SP@DOX)', which has an extremely high drug loading efficiency and PH-responsive drug sustained release, the chemotherapeutic doxorubicin (DOX) is simply added to '*S. platensis*' (SP). Because of the abundance of chlorophyll, 'SP@DOX' has outstanding in vivo tracking and real-time monitoring fluorescence imaging capabilities. The unsent carriers can finally be biologically broken down by renal clearance without significant harm.<sup>70 71</sup> Treatment options for patients depend on the presence of 'HER2' receptors, which are proteins produced by the 'HER2' gene. Breast tumors that are triple negative and hormone receptor-positive are classified as 'HER2'-negative. The 'HER2' subtype has a new classification called 'HER2'-low. It defines a new subtype of breast cancer that is not 'HER2'-positive but does have some 'HER2' proteins on the cell surface. Enhertu is approved for 'HER2'-low breast cancer patients who have already had chemotherapy for metastatic disease or whose cancer reappeared during or within six months after finishing adjuvant therapy.<sup>72 73</sup>

With '74 g' of "PUFAs" per kg of collected microalgae, "*Tetraselmis suecica*", marine green microalgae in the '*Chlorophyceae*' family, is particularly rich in biomolecules. When tested in the lab on the human pleural adenocarcinoma cell line "A549", its crude extract demonstrated significant antioxidant and cell-repairing activities.<sup>74</sup> The capacity of "A549" and "H460" lung cancer cells to form colonies has also been shown to be suppressed by an extract from a combination of microalgae when given in doses of 5 g/L. In addition, '*Chlorella vulgaris*' extract at a concentration of '200 g mL<sup>-1</sup>' significantly suppressed the proliferation and cell migration of the lung cancer cells "H1299", "A549", and "H1437". Human lung mucoepidermoid carcinoma "NCI-H292" cells were selectively affected by the ethanolic extracts of '*D. dichotoma*', '*P. gymnospora*' and '*H. musciformis*'. Other than microalgae, the lung tumor, along with any adjacent lymph nodes in the chest, are removed while the surgery. A border or margin of healthy lung tissue must be present near the tumor when it is removed.<sup>75</sup> For NSCLC, the following surgical procedures could be used:

**Lobectomy:** An complete lung lobe is removed during a lobectomy. Even when the lung tumor is relatively small, it is now believed to be the most effective kind of surgery.

**Segmentectomy:** A segmentectomy involves the surgeon removing the lung tissue where the cancer first appeared.

### Diatom-Based Nanocarrier Drug Delivery in Cancer Therapy

Minerals and secondary metabolites such as proteins, flavonoids, sterols, esters, acyl lipids, ester, and saturated and unsaturated fatty acids are abundant in diatoms. According to reports, these bioactive substances are effective anti-cancer, anti-bacterial agents, and antioxidant<sup>76-80</sup>. Due to their little growth cycles and high



production, diatoms are unicellular photosynthetic organisms that play a significant role in the biogeochemical circulation of silica, carbon, and nitrogen.<sup>81</sup> As it has a large surface area, bio-compatibility, nano-porosity, and biodegradability, the biosilica of diatoms has the potential

to be an effective drug delivery system for targeted cancer therapy. A diatoms-based technology may be suitable for use as a secure nanocarrier in nanomedicine applications because *in vivo* investigations on animal models have not revealed any discernible signs of tissue damage.<sup>82-85</sup>

**Table 4:** A list of the bioactive substances with anticancer effects on various cell lines that were obtained from various species of diatoms

Diatoms	Anticancer Compounds	Target cells
' <i>Synedra cause</i>	Chrysolaminaran	"Human colon cancer cells (HT-29)" "Colon cell line (DLD-1)"
	Nonyl 8-acetoxy-6- methyl octanoate (NAMO, fatty alcohol ester)	Human promyelocytic leukemia (HL-60). Human lung carcinoma (A549) Mouse melanoma (B16F10)
' <i>Cocconeis scutellum</i>	Fraction 3 (eicosapentaenoic acid (EPA), diethyl ether extract)	"Breast carcinoma (BT20)" "Human normal lymphocytes"
' <i>Chaetoceros calcitrans</i>	'AcOEt extract'	"Breast adenocarcinoma (MDA-MB-231)"
' <i>Skeletonema Marino</i>	Monoacylglycerides (MAGs)	"Colon cancer cell line (HCT-116)" "MePR-2B normal cells"

## CONCLUSION AND FUTURE ASPECTS

It is clear from the recent review that microalgae represent an exciting & successful research topic with a promising future. It offers details about microalgae and the bioactive substances found in them that have the potential to treat cancer. An efficient anti-tumorigenic and anti-proliferative action has been demonstrated by several biomolecule types that have been isolated and described from microalgal origin. As a result, '*U. pinnatifida*', '*S. horneri*', and '*H. elongata*' gathered during the peak Fx production period can be useful as strong sources of Fx. The molecular processes underpinning brown algae and Fx's cancer prevention in individuals with "colorectal cancer" (CRC) and 'CRC' animal models will need to be clarified through subsequent *in vitro* investigations, which will serve as a crucial foundation. There aren't many published studies on how taking FX directly combats CRC in humans. IBD, diabetes, obesity, inflammation, metabolic syndrome, hereditary factors, and oxidation are proposed as major risk factors causing colorectal carcinogenesis.

Advanced biological and molecular studies are still required to fully understand the function, effectiveness, and characterization of these anti-cancerous chemicals obtained from algal sources. Furthermore, in-depth studies should be conducted on the bioactive components of microalgae to assess their potential usefulness against a variety of cancers, whether *in-vitro* or *in vivo*.

## REFERENCES

- Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN. The REDCap consortium: building an international community of software platform partners. *Journal of biomedical informatics*. 2019 Jul 1;95:103208.
- Vandamme D, Foubert I, Meesschaert B, Muylaert K. Flocculation of microalgae using cationic starch. *Journal of applied Phycology*. 2010 Aug;22:525-30.
- Bastiaens L, Van Roy S, Thomassen G, Elst K. Biorefinery of algae: Technical and economic considerations. In *Microalgae-based biofuels and bioproducts 2017* Jan 1 (pp. 327-345). Woodhead Publishing.
- Lucas BF, de Morais MG, Santos TD, Costa JA. Spirulina for snack enrichment: Nutritional, physical, and sensory evaluations. *LWT*. 2018 Apr 1;90:270-6.
- Singh P, Singh R, Jha A, Rasane P, Gautam AK. Optimization of a process for high fiber and high protein biscuits. *Journal of food science and Technology*. 2015 Mar;52:1394-403.
- Jacobsen C, Let MB, Nielsen NS, Meyer AS. Antioxidant strategies for preventing oxidative flavor deterioration of foods enriched with n-3 polyunsaturated lipids: a comparative evaluation. *Trends in Food Science & Technology*. 2008 Feb 1;19(2):76-93.
- Banu JR, Kavitha S, Gunasekaran M, Kumar G. Microalgae based biorefinery promoting circular bioeconomy- techno economic and life-cycle analysis. *Bioresource technology*. 2020 Apr 1;302:122822.
- Rajesh Banu J, Kavitha S, Gunasekaran M, Kumar G. Microalgae based biorefinery promoting circular bioeconomy- techno economic and life-cycle analysis. *Bioresource technology*. 2020.
- Srivastava G, Paul AK, Goud VV. Optimization of non-catalytic transesterification of microalgae oil to biodiesel under supercritical methanol condition. *Energy Conversion and Management*. 2018 Jan 15;156:269-78.
- Chen CY, Yang YT. Combining engineering strategies and fermentation technology to enhance docosahexaenoic acid (DHA) production from an indigenous *Thraustochytrium* sp. BM2 strain. *Biochemical Engineering Journal*. 2018 May 15;133:179-85.
- García-Segovia P, Pagán-Moreno MJ, Lara IF, Martínez-Monzó J. Effect of microalgae incorporation on physicochemical and textural properties in wheat bread formulation. *Food Science and Technology International*. 2017 Jul;23(5):437-47.
- Boussiba S, Richmond AE. Isolation and characterization of



- phycocyanins from the blue-green alga *Spirulina platensis*. Archives of Microbiology. 1979 Feb;120:155-9.
13. Gouveia L, Batista AP, Miranda A, Empis J, Raymundo A. *Chlorella vulgaris* biomass used as colouring source in traditional butter cookies. Innovative food science & emerging technologies. 2007 Sep 1;8(3):433-6.
  14. Gouveia L, Batista AP, Miranda A, Empis J, Raymundo A. *Chlorella vulgaris* biomass used as colouring source in traditional butter cookies. Innovative food science & emerging technologies. 2007 Sep 1;8(3):433-6.
  15. Maneerote J, Noomhorm A, Takhar PS. Optimization of processing conditions to reduce oil uptake and enhance physico-chemical properties of deep fried rice crackers. LWT-Food Science and Technology. 2009 May 1;42(4):805-12.
  16. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. Growth inhibition of human tumor cell lines by withanolides from *Withania somnifera* leaves. Life sciences. 2003 Nov 21;74(1):125-32.
  17. Sharif N, Munir N, Saleem F, Aslam F, Naz S. Proliferic anticancer bioactivity of algal extracts. cell. 2014;3(4):8-21.
  18. Cha KH, Koo SY, Lee DU. Antiproliferative effects of carotenoids extracted from *Chlorella ellipsoidea* and *Chlorella vulgaris* on human colon cancer cells. Journal of agricultural and food chemistry. 2008 Nov 26;56(22):10521-6.
  19. Abd El-Hack ME, Abdelnour S, Alagawany M, Abdo M, Sakr MA, Khafaga AF, Mahgoub SA, Elnesr SS, Gebriel MG. Microalgae in modern cancer therapy: Current knowledge. Biomedicine & Pharmacotherapy. 2019 Mar 1;111:42-50.
  20. Ali HE, El-fayoumy EA, Rasmy WE, Soliman RM, Abdullah MA. Two-stage cultivation of *Chlorella vulgaris* using light and salt stress conditions for simultaneous production of lipids, carotenoids, and antioxidants. Journal of Applied Phycology. 2021 Feb;33:227-39.
  21. Hakim M, Patel I. Phytochemical evaluation, FT-IR and RP-HPLC Analysis of marine brown algae collected from the coastal area of Okha in Gujarat. Egyptian Journal of Agricultural Research. 2023 Mar 1;101(1):54-60.
  22. Dhandayuthapani K, Malathy S, Mulla SI, Gupta SK. An insight into the potential application of microalgae in pharmaceutical and nutraceutical production. Algae: Multifarious Applications for a Sustainable World. 2021:135-79.
  23. Sedjati S, Supriyanti E, Sulastri NI. Peningkatan Kadar Fenolik Total dari *Chlorella* sp. Menggunakan Cekaman Radiasi Ultraviolet-B. Jurnal Kelautan Tropis. 2023 Feb 23;26(1):49-58.
  24. Villarruel-López A, Ascencio F, Nuño K. Microalgae, a potential natural functional food source—a review. Polish Journal of Food and Nutrition Sciences. 2017;67(4).
  25. Barsanti L, Coltelli P, Evangelista V, Frassanito AM, Passarelli V, Vesentini N, Gualtieri P. Oddities and curiosities in the algal world. In: Algal toxins: nature, occurrence, effect, and detection 2008 (pp. 353-391). Springer Netherlands.
  26. Das P, Aziz SS, Obbard JP. Two phase microalgae growth in the open system forenhanced lipid productivity. Renewable Energy. 2011 Sep 1;36(9):2524-8.
  27. Yuan YV, Walsh NA. Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food and chemical toxicology. 2006 Jul 1;44(7):1144-50.
  28. Schaller A. Bioactive peptides as signal molecules in plant defense, growth, and development. Studies in natural products chemistry. 2001 Jan 1;25:367-411.
  29. J Boohaker R, W Lee M, Vishnubhotla P, LM Perez J, R Khaled A. The use of therapeutic peptides to target and to kill cancer cells. Current medicinal chemistry. 2012 Aug 1;19(22):3794-804.
  30. Liu L, Heinrich M, Myers S, Dworjanyn SA. Towards a better understanding of medicinal uses of the brown seaweed *Sargassum* in Traditional Chinese Medicine: A phytochemical and pharmacological review. Journal of ethnopharmacology. 2012 Aug 1;142(3):591-619.
  31. Liu L, Heinrich M, Myers SP, Dworjanyn SA. Towards a better understanding of medicinal uses of the brown seaweed genus *Sargassum* in traditional Chinese medicine: a phytochemical and pharmacological review.
  32. Landsberg JH. Toxins and harmful mechanisms. The Effect of Harmful Algal Bloomson Aquatic Organisms. 2002;10:191-3.
  33. Caldwell GS. The influence of bioactive oxylipins from marine diatoms on invertebrate reproduction and development. Marine Drugs. 2009 Aug 21;7(3):367-400.
  34. Swapnil S, Bruno B, Udhaya R, Krishna K, Sandhya S, Waman P. Bioactive compounds derived from microalgae showing antimicrobial activities. Journal of Aquaculture research and Development. 2014;5(3).
  35. Ibrahim K, Ramli R, Abdul Rashid AH, Mohd Yusof YA. Antimicrobial Property of Water and Ethanol Extract *Chlorella vulgaris*: A Value-Added Advantage for a New Wound Dressing Material. International Medical Journal. 2015 Oct 1;22(5).
  36. Martínez Andrade KA, Lauritano C, Romano G, lanora A. Marine microalgae with anti-cancer properties. Marine drugs. 2018 May 15;16(5):165.
  37. Borowitzka MA. High-value products from microalgae—their development and commercialisation. Journal of applied phycology. 2013 Jun;25:743-56.
  38. de Morais MG, Vaz BD, de Morais EG, Costa JA. Biologically active metabolites synthesized by microalgae. BioMed research is international. 2015 Aug 3;2015.
  39. Chacón-Lee TL, González-Mariño GE. Microalgae for “healthy” foods—possibilities and challenges. Comprehensive reviews in food science and food safety. 2010 Nov;9(6):655-75.
  40. Milledge JJ. Commercial application of microalgae other than as biofuels: a brief review. Reviews in Environmental Science and Bio/Technology. 2011 Mar;10:31-41.
  41. Ahsan M, Habib B, Parvin M, Huntington TC, Hasan MR. A review on culture, production, and use of spirulina as food for humans and feeds for domestic animals.
  42. John DM, Whitton BA, Brook AJ, editors. The freshwater algal flora of the British Isles: An identification guide to freshwater and terrestrial algae. Cambridge University Press; 2002 Apr 25.
  43. Shanab SM, Mostafa SS, Shalaby EA, Mahmoud GI. Aqueous extracts of microalgae exhibit antioxidant and anticancer activities. Asian Pacific Journal of Tropical Biomedicine. 2012 Aug 1;2(8):608-15.
  44. De Morais MG, Vaz BS, De Morais EG, Costa JA. Biologically active metabolites synthesized by microalgae. Biomed Research International.
  45. Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012 Apr 16;2(2):303-36.
  46. David B, Wolfender JL, Dias DA. The pharmaceutical industry and natural products: historical status and new trends. Phytochemistry Reviews. 2015 Apr;14:299-315.
  47. Lee JC, Hou MF, Huang HW, Chang FR, Yeh CC, Tang JY, Chang HW. Marine algal natural products with anti-oxidative, anti-inflammatory, and anti-cancer properties. Cancer cell international. 2013 Dec;13:1-7.
  48. Farooqi AA, Butt G, Razzaq Z. Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of ‘the dance macabre’. Cancer cell international. 2012 Dec;12(1):1-6.
  49. Talero E, García-Mauriño S, Ávila-Román J, Rodríguez-Luna A, Alcaide A, Motilva V. Bioactive compounds isolated from microalgae in chronic inflammation and cancer. Marine drugs. 2015 Sep 30;13(10):6152-209.
  50. Peng J, Yuan JP, Wu CF, Wang JH. Fucoxanthin, a marine carotenoid present in brownseaweeds and diatoms: metabolism and bioactivities relevant to human health. Marine drugs. 2011 Oct 10;9(10):1806-28.
  51. Breslauer DN, Maamari RN, Switz NA, Lam WA, Fletcher DA. Mobile phone based clinical microscopy for global health applications. PLoS one. 2009 Jul 22;4(7):e6320.
  52. Campbell NA, Reece JB. Biology. Pearson Education India; 2005.
  53. Bromham N, Kallioinen M, Hoskin P, Davies RJ. Colorectal cancer: summary of NICE guidance. BMJ. 2020 Mar 2;368.





54. Kelsey JL. Breast cancer epidemiology: summary and future directions. *Epidemiologic reviews*. 1993;15(1):256-63.
55. Kelley MJ, McCrory DC. Prevention of lung cancer: summary of published evidence. *Chest*. 2003 Jan 1;123(1):50S-9S.
56. Wang Z, Li H, Dong M, Zhu P, Cai Y. The anticancer effects and mechanisms of fucoxanthin combined with other drugs. *Journal of Cancer Research and Clinical Oncology*. 2019 Feb 13;145:293-301.
57. Fayyad RJ, Ali AN, Hamdan NT. The Specific Anti-cancerous Mechanisms Suggesting Spirulina Alga as a Promising breast Cancer Fighter. *Research Journal of Pharmacy and Technology*. 2021;14(10):5599-602.
58. Saadaoui I, Rasheed R, Abdulrahman N, Bounnit T, Cherif M, Al Jabri H, Mraiche F. Algae-derived bioactive compounds with anti-lung cancer potential. *Marine drugs*. 2020 Apr 8;18(4):197.
59. Tang M. Identifying opportunities to cultivate algae combined with wastewater recycling as a source of renewable energy in Southeast Asia (Doctoral dissertation, Murdoch University).
60. Hussein HA, Abdullah MA. Anticancer compounds derived from marine diatoms. *Marine Drugs*. 2020 Jul 9;18(7):356.
61. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. Growth inhibition of human tumor cell lines by withanolides from *Withania somnifera* leaves. *Life sciences*. 2003 Nov 21;74(1):125-32.
62. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. Growth inhibition of human tumor cell lines by withanolides from *Withania somnifera* leaves. *Life sciences*. 2003 Nov 21;74(1):125-32.
63. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. *Journal of ethnopharmacology*. 2005 Aug 22;100(1-2):72-9.
64. Abd El-Baky HH, El Baz FK, El-Baroty GS. Production of phenolic compounds from *Spirulina maxima* microalgae and its protective effects in vitro toward hepatotoxicity model. *African Journal of Pharmacy and Pharmacology*. 2009 Apr;3(4):133-9.
65. Abd El Baky HH, El Baroty GS. Optimization of growth conditions for purification and production of L-asparaginase by *Spirulina maxima*. *Evidence-Based Complementary and Alternative Medicine*. 2016 Jan 1;2016.
66. Abdel-Latif MM, Babar M, Kelleher D, Reynolds JV. A pilot study of the impact of Vitamin C supplementation with neoadjuvant chemoradiation on regulators of inflammation and carcinogenesis in esophageal cancer patients. *Journal of cancer research and therapeutics*. 2019 Jan 1;15(1):185-91.
67. Abdel-Samad R, Aouad P, Darwiche N. Natural and synthetic retinoids in preclinical colorectal cancer models. *Anti-Cancer Drugs*. 2019 Aug 1;30(7):655-69.
68. Abraham A, Kattoor AJ, Saldeen T, Mehta JL. Vitamin E and its anticancer effects. *Critical reviews in food science and nutrition*. 2019 Sep 25;59(17):2831-8.
69. Ahmed F, Fanning K, Netzel M, Turner W, Li Y, Schenk PM. Profiling of carotenoids and antioxidant capacity of microalgae from subtropical coastal and brackish waters. *Food chemistry*. 2014 Dec 15;165:300-6.
70. Akiba T, Morikawa T, Odaka M, Nakada T, Kamiya N, Yamashita M, Yabe M, Inagaki T, Asano H, Mori S, Tsukamoto Y. Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial RCT of Vitamin D for Lung Cancer. *Clinical Cancer Research*. 2018 Sep 1;24(17):4089-97.
71. Ambati RR, Siew Moi P, Ravi S, Aswathanarayana RG. Astaxanthin: Sources, extraction, stability, biological activities and its commercial applications—A review. *Marine drugs*. 2014 Jan 7;12(1):128-52.
72. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). *Journal of clinical oncology*. 2020 Mar 3;38(8):804.
73. Amna Kashif S, Hwang YJ, Park JK. Potent biomedical applications of isolated polysaccharides from marine microalgae *Tetraselmis* species. *Bioprocess and biosystems engineering*. 2018 Nov;41:1611-20.
74. Ansari H, Nouranian M, Hajigholami A, Mahmudian A. Effect of omega-3 fatty acid supplements on cancer-related fatigue in an outpatient setting: a randomized controlled trial. *Middle East Journal of Cancer*. 2019 Oct 1;10(4):333-40.
75. Ferdous UT, Yusof ZN. Medicinal prospects of antioxidants from algal sources in cancer therapy. *Frontiers in Pharmacology*. 2021 Mar 5;12:593116.
76. Ashfaq W, Rehman K, Siddique MI, Khan QA. Eicosapentaenoic acid and docosahexaenoic acid from fish oil and their role in cancer research. *Food Reviews International*. 2020 Nov 16;36(8):795-814.
77. Dyshlovoy SA, Honecker F. Marine compounds and cancer: where do we stand? *Marine Drugs*. 2015 Sep 2;13(9):5657-65.
78. Jaspars M, De Pascale D, Andersen JH, Reyes F, Crawford AD, Ianora A. The marine biodiversity pipeline and ocean medicines of tomorrow. *Journal of the Marine Biological Association of the United Kingdom*. 2016 Feb;96(1):151-8.
79. Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. *JACC: Basic to Translational Science*. 2016 Apr;1(3):170-9.
80. Lauritano C, Andersen JH, Hansen E, Albrigtsen M, Escalera L, Esposito F, Helland K, Hanssen KØ, Romano G, Ianora A. Bioactivity screening of microalgae for antioxidant, anti-inflammatory, anticancer, anti-diabetes, and antibacterial activities. *Frontiers in marine science*. 2016 May 10;3:68.
81. Ballesteros-Torres JM, Samaniego-Moreno L, Gomez-Flores R, Tamez-Guerra RS, Rodríguez-Padilla C, Tamez-Guerra P. Amino acids and acylcarnitine production by *Chlorella vulgaris* and *Chlorella sorokiniana* microalgae from wastewater culture. *PeerJ*. 2019 Dec 3;7:e7977.
82. Ballesteros-Torres JM, Samaniego-Moreno L, Gomez-Flores R, Tamez-Guerra RS, Rodríguez-Padilla C, Tamez-Guerra P. Amino acids and acylcarnitine production by *Chlorella vulgaris* and *Chlorella sorokiniana* microalgae from wastewater culture. *PeerJ*. 2019 Dec 3;7:e7977.
83. Banskota AH, Sperker S, Stefanova R, McGinn PJ, O'Leary SJ. Antioxidant properties and lipid composition of selected microalgae. *Journal of Applied Phycology*. 2019 Feb;31:309-18.
84. Baudalet PH, Gagez AL, Bérard JB, Juin C, Bridiau N, Kaas R, Thiéry V, Cadoret JP, Picot L. Antiproliferative activity of Cyanophora paradoxa pigments in melanoma, breast, and lung cancer cells. *Marine Drugs*. 2013 Nov 1;11(11):4390-406.
85. Sharif N, Munir N, Saleem F, Aslam F, Naz S. Proliferative anticancer bioactivity of algal extracts. *cell*. 2014;3(4):8-21.

**Source of Support:** The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Conflict of Interest:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any questions related to this article, please reach us at: [globalresearchonline@rediffmail.com](mailto:globalresearchonline@rediffmail.com)

New manuscripts for publication can be submitted at: [submit@globalresearchonline.net](mailto:submit@globalresearchonline.net) and [submit\\_ijpsrr@rediffmail.com](mailto:submit_ijpsrr@rediffmail.com)

